Soligenix Provides Regulatory Update on HyBryte(TM)

PRINCETON, N.J., April 14, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where ... Biopharmaceuticals, Oncology, FDA Soligenix, HyBryte, synthetic hypericin sodium, CTCL
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news